- Molecular NameEthinamate
- SynonymEthinamat; Ethinimate; Etinamate; USAF EL-42
- Weight167.208
- Drugbank_IDDB01031
- ACS_NO126-52-3
- Show 3D model
- LogP (experiment)1.514
- LogP (predicted, AB/LogP v2.0)1.57
- pkaN/A
- LogD (pH=7, predicted)1.57
- Solubility (experiment)2.5 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.69
- LogSw (predicted, AB/LogsW2.0)3.54
- Sw (mg/ml) (predicted, ACD/Labs)3.44
- No.of HBond Donors2
- No.of HBond Acceptors3
- No.of Rotatable Bonds3
- TPSA52.32
- StatusFDA approved
- AdministrationN/A
- PharmacologyA short-acting carbamate-derivitive sedative-hypnotic medication used to treat insomnia.
- Absorption_valueN/A
- Absorption (description)Rapidly absorbed after oral administration.
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolised by hydroxylation to 4-hydroxyethinamate, which exists as stereoisomers, and conjugated with glucuronic acid.
- Half life2 h
- ExcretionAbout 40% of a dose is excreted in the urine in 24 h as trans-4-hydroxyethinamate or its glucuronide conjugate; only a small amount is excreted unchanged in the urine; 3- and 2-hydroxyethinamate have also been detected in urine.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include shortness of breath or slow or troubled breathing, slow heartbeat, severe weakness, chronic confusion, slurred speech, and staggering.. The estimated minimum lethal dose is 15 g but recovery has occurred after ingestion of as much as 28 g. Prolonged use of ethinamate may lead to dependence of the barbiturate–alcohol type. Blood concentrations greater than 100 mg/L have been associated with fatalities.
- LD50 (rat)N/A
- LD50 (mouse)LD50=554